Research Updates

Back to feed
Clinical trials
Registered study

High importance

Oct 22, 2026

Quality of Life in Pediatric Participants With HHT

View original source

Why it matters

Understanding HR-QoL in pediatric patients with HHT is critical for personalized care strategies, guiding treatment decisions, and improving overall patient management.

Objective

To evaluate health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT).

Results

The study aims to provide mean HR-QoL scores for the target population and reveal associations between these scores, disease severity, and clinical procedures, thus contributing to the understanding of HHT's impact on daily life.

Methods

Participants, including pediatric patients and their caregivers, completed validated HR-QoL questionnaires covering physical, emotional, social, and disease-specific functioning over a 30-day period. A retrospective chart review assessed disease severity and clinical resource utilization.

Limitations

The observational design may limit causal inferences, and the results may not be generalizable beyond the studied population due to the specific setting at Cincinnati Children's Hospital.

For your doctor:

ClinicalTrials.gov: NCT07474428

Abstract

This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT). Eligible participants are patients receiving care at Cincinnati Children's Hospital Medical Center and / or their caregivers. Participants will complete validated quality-of-life questionnaires assessing physical, emotional, social, and disease-specific functioning over the past 30 days. A paired retrospective chart review will assess disease severity and clinical utilization, including procedures and imaging studies. The primary objective is to describe mean QoL scores for this population. Secondary objectives include evaluating associations between QoL scores, disease severity, and clinical utilization.